With a 94% gross margin, I'm staying invested.
The quarterly results from Krystal Biotech were strong and exceeded expectations. Nevertheless, the stock fell after the release because investors apparently focus more on margins, continued growth momentum, and the pipeline than on the quarter alone. [de.investing.com]
Key Takeaways
✅ Revenue and profit exceeded expectations
- Revenue: $127.3 million (+30% YoY)
- Diluted EPS: $2.05 (Expected: $1.84)
- Both revenue and earnings estimates were exceeded. [de.investing.com]
✅ VYJUVEK remains the growth driver
- VYJUVEK generated $127.3 million in quarterly revenue.
- Since its market launch, cumulative revenue has already reached approximately $1.1 billion in cumulative revenue has been achieved.
- International expansion in Europe and Japan is increasingly contributing to growth. [de.investing.com]
✅ Extremely strong balance sheet
- $1.2 billion in cash and securities
- New share buyback program worth $400 million over the next two years. [de.investing.com]
So why is the stock still falling?
⚠️ Margin pressure
- Gross margin fell from 96% to 94%.
- International sales are currently less profitable than U.S. sales. [de.investing.com]
⚠️ Profit down from the previous year
- Although EPS exceeded expectations, it was below the prior-year figure of $2.66.
- Net income also fell from $79.4 million to $63.1 million. [de.investing.com]
⚠️ Dependence on a Single Product
- VYJUVEK remains the dominant revenue driver.
- Investors want to see evidence that the pipeline can produce more blockbusters. [de.investing.com]
Outlook
Several pipeline catalysts are on the horizon:
- KB111 (Hailey-Hailey disease): Data expected in 2026
- KB803 (ocular DEB): Results in 2027
- KB407 (cystic fibrosis): Interim data in 2027
- KB801 (neurotrophic keratopathy): Results in 2027
- Other programs in oncology and rare diseases are also continuing. [de.investing.com]
Juan’s Assessment 🎯
Bullish:
- 30% revenue growth
- Huge cash position
- Gross margin remains exceptionally high
- Share buyback program
- Several potential catalysts in the pipeline [de.investing.com]
Risks:
- High dependence on VYJUVEK
- Decline in margins
- Delays in clinical trials could weigh on the valuation [de.investing.com]
My overall impression: The report appears fundamentally strong to very strong. The decline in the stock price appears to be more a reaction to expectations and slight margin pressure than to a deterioration in the core business. For me, as a long-term investor, the pipeline remains the decisive factor over the next 12 to 18 months.
